Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorbipiprant plus balstilimab in pretreated metastatic colorectal and other gastrointestinal cancers
2024-515446-16-00Phase 2Authorised
- Sponsor
- Rottapharm Biotech
- Start
- Aug 2024
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vorbipiprant and balstilimab in colorectal cancer (CRC), gastric cancer (GC), gastroesophageal junction adenocarcinoma and 1 more (4 arms), sponsored by Rottapharm Biotech. Primary endpoints: Incidence of dose-limiting toxicities, Incidence of treatment-emergent adverse events and 4 more. Planned start Aug 2024; status: authorised.
02
Drugs
vorbipiprantbalstilimab
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)gastroesophageal junction adenocarcinomagastrointestinal cancer
Beyond the preview
Go deeper on 2024-515446-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515446-16-00.